S&P 500   3,166.41 (-0.07%)
DOW   28,110.79 (-0.08%)
QQQ   207.04 (+0.26%)
AAPL   274.11 (+0.98%)
FB   194.43 (-1.18%)
MSFT   154.55 (+0.85%)
GOOGL   1,345.61 (-0.21%)
AMZN   1,763.88 (+0.20%)
CGC   21.60 (+2.18%)
NVDA   224.07 (+0.00%)
MU   51.32 (+0.69%)
BABA   204.74 (+0.12%)
T   38.04 (-0.83%)
AMD   41.66 (-2.18%)
ACB   2.66 (+2.31%)
F   9.21 (-1.29%)
NFLX   298.80 (+0.12%)
BAC   34.50 (-0.55%)
GILD   65.99 (-2.43%)
S&P 500   3,166.41 (-0.07%)
DOW   28,110.79 (-0.08%)
QQQ   207.04 (+0.26%)
AAPL   274.11 (+0.98%)
FB   194.43 (-1.18%)
MSFT   154.55 (+0.85%)
GOOGL   1,345.61 (-0.21%)
AMZN   1,763.88 (+0.20%)
CGC   21.60 (+2.18%)
NVDA   224.07 (+0.00%)
MU   51.32 (+0.69%)
BABA   204.74 (+0.12%)
T   38.04 (-0.83%)
AMD   41.66 (-2.18%)
ACB   2.66 (+2.31%)
F   9.21 (-1.29%)
NFLX   298.80 (+0.12%)
BAC   34.50 (-0.55%)
GILD   65.99 (-2.43%)
S&P 500   3,166.41 (-0.07%)
DOW   28,110.79 (-0.08%)
QQQ   207.04 (+0.26%)
AAPL   274.11 (+0.98%)
FB   194.43 (-1.18%)
MSFT   154.55 (+0.85%)
GOOGL   1,345.61 (-0.21%)
AMZN   1,763.88 (+0.20%)
CGC   21.60 (+2.18%)
NVDA   224.07 (+0.00%)
MU   51.32 (+0.69%)
BABA   204.74 (+0.12%)
T   38.04 (-0.83%)
AMD   41.66 (-2.18%)
ACB   2.66 (+2.31%)
F   9.21 (-1.29%)
NFLX   298.80 (+0.12%)
BAC   34.50 (-0.55%)
GILD   65.99 (-2.43%)
S&P 500   3,166.41 (-0.07%)
DOW   28,110.79 (-0.08%)
QQQ   207.04 (+0.26%)
AAPL   274.11 (+0.98%)
FB   194.43 (-1.18%)
MSFT   154.55 (+0.85%)
GOOGL   1,345.61 (-0.21%)
AMZN   1,763.88 (+0.20%)
CGC   21.60 (+2.18%)
NVDA   224.07 (+0.00%)
MU   51.32 (+0.69%)
BABA   204.74 (+0.12%)
T   38.04 (-0.83%)
AMD   41.66 (-2.18%)
ACB   2.66 (+2.31%)
F   9.21 (-1.29%)
NFLX   298.80 (+0.12%)
BAC   34.50 (-0.55%)
GILD   65.99 (-2.43%)
Log in

NYSE:GMED - Globus Medical Stock Price, Forecast & News

$57.90
+0.11 (+0.19 %)
(As of 12/13/2019 12:01 PM ET)
Today's Range
$57.46
Now: $57.90
$58.35
50-Day Range
$49.51
MA: $54.51
$57.73
52-Week Range
$38.01
Now: $57.90
$58.25
Volume132,654 shs
Average Volume524,523 shs
Market Capitalization$5.76 billion
P/E Ratio34.67
Dividend YieldN/A
Beta0.96
Globus Medical, Inc, a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its spine product portfolio includes a range of implant and surgical approach options that could be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP37957720
Phone610-930-1800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$712.97 million
Cash Flow$2.20 per share
Book Value$12.03 per share

Profitability

Net Income$156.47 million

Miscellaneous

Employees1,800
Market Cap$5.76 billion
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable

Receive GMED News and Ratings via Email

Sign-up to receive the latest news and ratings for GMED and its competitors with MarketBeat's FREE daily newsletter.


Globus Medical (NYSE:GMED) Frequently Asked Questions

What is Globus Medical's stock symbol?

Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED."

How were Globus Medical's earnings last quarter?

Globus Medical Inc (NYSE:GMED) released its earnings results on Wednesday, November, 6th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.42 by $0.01. The medical device company had revenue of $196.22 million for the quarter, compared to analysts' expectations of $185.86 million. Globus Medical had a return on equity of 13.09% and a net margin of 19.03%. The firm's quarterly revenue was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.39 EPS. View Globus Medical's Earnings History.

When is Globus Medical's next earnings date?

Globus Medical is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Globus Medical.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical updated its FY19 earnings guidance on Wednesday, November, 6th. The company provided EPS guidance of $1.72 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.72. The company issued revenue guidance of $783 million from $775 million, compared to the consensus revenue estimate of $775.86 million.

What price target have analysts set for GMED?

8 equities research analysts have issued twelve-month price objectives for Globus Medical's stock. Their forecasts range from $45.00 to $64.00. On average, they expect Globus Medical's share price to reach $57.17 in the next year. This suggests that the stock has a possible downside of 1.3%. View Analyst Price Targets for Globus Medical.

What is the consensus analysts' recommendation for Globus Medical?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Globus Medical.

What are Wall Street analysts saying about Globus Medical stock?

Here are some recent quotes from research analysts about Globus Medical stock:
  • 1. According to Zacks Investment Research, "Globus Medical witnessed strength in the United States and the international regions as well as in the Musculoskeletal solutions and Enabling Technologies segments. Implant pull-through from ExcelsiusGPS placements and back-to-back record sales force recruiting years were the primary growth drivers. Internationally, spine business grew by 15% in the third quarter, ahead of the market in almost all significant geographies.Globus Medical posted mixed third-quarter results with earnings meeting the Zacks Consensus Estimate and revenues beating the mark.Globus Medical has outperformed its industry in the past three months. However, the pricing scenario is persistently tough for Globus Medical." (12/13/2019)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating on GMED with a 12-month price target of $60. We think GMED has several top-line growth drivers, including a US core market rebound, early success of emerging technologies and traction of the acquired ATEC international platform. GMED’s best-in-class profitability allows the company to invest organically or inorganically to drive top-line growth and to react to the evolving trends of the spine market. These should bring the company back to the beat-and-raise philosophy of a couple of years ago and help to push the valuation higher." (3/1/2019)

Has Globus Medical been receiving favorable news coverage?

News articles about GMED stock have been trending positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Globus Medical earned a news sentiment score of 2.1 on InfoTrie's scale. They also assigned news articles about the medical device company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Globus Medical.

Are investors shorting Globus Medical?

Globus Medical saw a drop in short interest in the month of November. As of November 15th, there was short interest totalling 1,610,000 shares, a drop of 18.7% from the October 31st total of 1,980,000 shares. Based on an average daily trading volume, of 446,900 shares, the short-interest ratio is currently 3.6 days. Approximately 2.1% of the shares of the company are short sold. View Globus Medical's Current Options Chain.

Who are some of Globus Medical's key competitors?

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include AbbVie (ABBV), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY), Alibaba Group (BABA), Novartis (NVS), Intuitive Surgical (ISRG), Bausch Health Companies (BHC), Johnson & Johnson (JNJ), Intel (INTC) and NVIDIA (NVDA).

Who are Globus Medical's key executives?

Globus Medical's management team includes the folowing people:
  • Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 52)
  • Mr. David M. Demski, CEO & Director (Age 61)
  • Mr. Anthony L. Williams, Pres & Corp. Sec. (Age 48)
  • Mr. David D. Davidar, Co-Founder & Director (Age 53)
  • Mr. Daniel T. Scavilla, CFO, Exec. VP & Chief Commercial Officer (Age 54)

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (2.58%), GW&K Investment Management LLC (1.46%), Marathon Asset Management LLP (0.73%), Boston Trust Walden Corp (0.43%), Pembroke Management LTD (0.37%) and Retirement Systems of Alabama (0.35%). Company insiders that own Globus Medical stock include Anthony L Williams, Daniel T Scavilla, David C Paul, David D Davidar, David M Demski, Eric Schwartz, James R Tobin, Kelly Huller and Steven Payne. View Institutional Ownership Trends for Globus Medical.

Which institutional investors are selling Globus Medical stock?

GMED stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Sterling Investment Advisors Ltd., Marathon Asset Management LLP, SG Americas Securities LLC, Russell Investments Group Ltd., Man Group plc, Tower Research Capital LLC TRC and Stifel Financial Corp. Company insiders that have sold Globus Medical company stock in the last year include Anthony L Williams, David D Davidar, James R Tobin and Kelly Huller. View Insider Buying and Selling for Globus Medical.

Which institutional investors are buying Globus Medical stock?

GMED stock was acquired by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Boston Trust Walden Corp, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Point72 Asset Management L.P., Millennium Management LLC, Pembroke Management LTD and Mackay Shields LLC. View Insider Buying and Selling for Globus Medical.

How do I buy shares of Globus Medical?

Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Globus Medical's stock price today?

One share of GMED stock can currently be purchased for approximately $57.90.

How big of a company is Globus Medical?

Globus Medical has a market capitalization of $5.76 billion and generates $712.97 million in revenue each year. The medical device company earns $156.47 million in net income (profit) each year or $1.67 on an earnings per share basis. Globus Medical employs 1,800 workers across the globe.View Additional Information About Globus Medical.

What is Globus Medical's official website?

The official website for Globus Medical is http://www.globusmedical.com/.

How can I contact Globus Medical?

Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The medical device company can be reached via phone at 610-930-1800 or via email at [email protected]


MarketBeat Community Rating for Globus Medical (NYSE GMED)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  456 (Vote Outperform)
Underperform Votes:  381 (Vote Underperform)
Total Votes:  837
MarketBeat's community ratings are surveys of what our community members think about Globus Medical and other stocks. Vote "Outperform" if you believe GMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel